Achieving a clinically relevant composite outcome of an HbA1c of &lt;7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme.

Zinman, B; Schmidt, W; Moses, A; Lund, N; Gough, S

Journal article

Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme.

Abstract:: AIM: Effective type 2 diabetes management requires a multifactorial approach extending beyond glycaemic control. Clinical practice guidelines suggest targets for HbA1c, blood pressure and lipids, and emphasize weight reduction and avoiding hypoglycaemia. The phase 3 clinical trial programme for liraglutide, a human glucagon-like peptide 1 analogue, showed significant improvements in HbA1c and weight with a low risk of hypoglycaemia compared to other diabetes therapies. In this context, we performed a meta-analysis of data from these trials evaluating the proportion of patients achieving a clinically relevant composite measure of diabetes control consisting of an HbA1c <7% without weight gain or hypoglycaemia. METHODS: A prespecified meta-analysis was performed on 26-week patient-level data from seven trials (N = 4625) evaluating liraglutide with commonly used therapies for type 2 diabetes: glimepiride, rosiglitazone, glargine, exenatide, sitagliptin or placebo, adjusting for baseline HbA1c and weight, for a composite outcome of HbA1c <7.0%, no weight gain and no hypoglycaemic events. RESULTS: At 26 weeks, 40% of the liraglutide 1.8 mg group, 32% of the liraglutide 1.2 mg group and 6-25% of comparators (6% rosiglitazone, 8% glimepiride, 15% glargine, 25% exenatide, 11% sitagliptin, 8% placebo) achieved this composite outcome. Odds ratios favoured liraglutide 1.8 mg by 2.0- to 10.5-fold over comparators. CONCLUSIONS: As assessed by the composite outcome of HbA1c <7%, no hypoglycaemia and no weight gain, liraglutide was clearly superior to the other commonly used therapies. However, the long-term clinical impact of this observation remains to be shown.

Publication status:: Published

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Zinman, B., Schmidt, W., Moses, A., Lund, N., & Gough, S. (2012). Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes, Obesity and Metabolism, 14(1), 77–82.

MLA Style

Zinman, B, et al. “Achieving a Clinically Relevant Composite Outcome of an HbA1c of 7% without Weight Gain or Hypoglycaemia in Type 2 Diabetes: a Meta-Analysis of the Liraglutide Clinical Trial Programme.” Diabetes, Obesity and Metabolism, vol. 14, no. 1, 2012, pp. 77–82.

Chicago Style

Zinman, B, W Schmidt, A Moses, N Lund, and S Gough. 2012. “Achieving a Clinically Relevant Composite Outcome of an HbA1c of 7% without Weight Gain or Hypoglycaemia in Type 2 Diabetes: a Meta-Analysis of the Liraglutide Clinical Trial Programme.” Diabetes, Obesity and Metabolism 14 (1): 77–82.
Print